Endocrine Unit, Thier 10, 50 Blossum Street, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
J Clin Endocrinol Metab. 2010 Feb;95(2):578-85. doi: 10.1210/jc.2009-1603. Epub 2009 Dec 4.
Fibroblast growth factor 23 (FGF23) regulates phosphorus homeostasis and vitamin D metabolism. Circulating FGF23 levels are elevated in inherited and acquired hypophosphatemic disorders that can cause rickets or osteomalacia. Particularly increased concentrations of FGF23 are observed in patients with chronic kidney disease (CKD), in which increased FGF23 is associated with more rapid disease progression, improved bone mineralization, the development of left ventricular hypertrophy, and increased mortality.
Our objective was to determine whether the markedly elevated levels of immunoreactive FGF23 in CKD represent accumulation of intact, biologically active hormone, C-terminal cleavage fragments, or both.
Biologically active FGF23 in plasma from CKD patients treated by peritoneal dialysis was quantified using a cell-based Egr-1 reporter assay; bioactive FGF23 levels were compared with those measured with immunometric FGF23 assays detecting either intact hormone alone or intact hormone and C-terminal fragments.
Adult and pediatric patients with end-stage renal disease treated with peritoneal dialysis participated in the study at a tertiary referral center.
Serially diluted patient samples revealed levels of bioactive FGF23 that ran in parallel to CHO cell-derived recombinant human FGF23. FGF23 bioactivity was inhibited by an anti-FGF23 antibody. Levels of bioactive and immunoreactive FGF23 were tightly correlated, and Western blot analysis of FGF23 immunoprecipitated with anti-FGF23 antibodies from plasma of dialysis patients revealed only a single prominent protein band, which was indistinguishable from recombinant intact FGF23, without clear evidence for FGF23 fragments.
Our results provide strong evidence for the conclusion that virtually all circulating FGF23 in dialysis patients is intact and biologically active.
成纤维细胞生长因子 23(FGF23)调节磷稳态和维生素 D 代谢。在遗传性和获得性低磷血症疾病中,循环 FGF23 水平升高,可导致佝偻病或骨软化症。在慢性肾脏病(CKD)患者中尤其观察到 FGF23 浓度显著升高,其中 FGF23 增加与疾病进展更快、骨矿物质化改善、左心室肥厚发展和死亡率增加相关。
我们的目的是确定 CKD 中明显升高的免疫反应性 FGF23 水平是否代表完整的、具有生物活性的激素、C 端裂解片段或两者的积累。
使用基于细胞的 Egr-1 报告基因测定法,定量测定腹膜透析治疗的 CKD 患者血浆中的生物活性 FGF23;将生物活性 FGF23 水平与免疫测定法检测的完整激素或完整激素和 C 端片段的免疫测定法测量的水平进行比较。
在三级转诊中心参加研究的接受腹膜透析治疗的终末期肾病的成年和儿科患者。
连续稀释患者样本显示出与 CHO 细胞衍生的重组人 FGF23 平行的生物活性 FGF23 水平。FGF23 生物活性被抗 FGF23 抗体抑制。生物活性和免疫活性 FGF23 水平密切相关,用抗 FGF23 抗体从透析患者的血浆中免疫沉淀 FGF23 进行 Western blot 分析仅显示一条单一的明显蛋白带,与重组完整 FGF23 无法区分,没有 FGF23 片段的明确证据。
我们的结果为几乎所有在透析患者中循环的 FGF23 都是完整和具有生物活性的这一结论提供了有力证据。